Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental obesity pill, with increased weight loss at higher doses, IBD’s Ed Carson reports. Patients taking 100-miligram doses of Viking’s VK2735 lost 8.2% of their body weight after 28 days, or 6.8% more than those taking a placebo, and no patients taking the highest dose stopped taking it, according to the report. Other companies that make weight-loss drugs include Eli Lilly (LLY) and Novi Nordisk (NVO). Shares of Viking Therapeutics were up nearly 25% in premarket trading.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Boeing union rejects latest offer, Tesla reports Q3 beat: Morning Buzz
- Viking Therapeutics reports Q3 EPS (22c) , consensus (25c)
- Viking Therapeutics options imply 8.5% move in share price post-earnings
- Is VKTX a Buy, Before Earnings?
- Viking Therapeutics reports data from Phase 1b clinical trial of VK0214